Search
Potassium bicarbonate
go.drugbank.com/drugs/DB11098ApprovedInvestigationalIt is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid.
Mixtures: Neo K, POT-K 1,56 G EFERVESAN TABLET, 60 ADETProducts: Effer-K Orange, Effer-K UnflavoredEnmetazobactam
go.drugbank.com/drugs/DB18716ApprovedInvestigational[A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections. … [L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.
Lazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.
Synonyms: N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE, 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-Ioxitalamic acid
go.drugbank.com/drugs/DB13444ApprovedWithdrawn[A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995. … [A27209] It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg.
Fusidic acid
go.drugbank.com/drugs/DB02703ApprovedInvestigationalIt is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections. … (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis.
Mixtures: ACELER-COPegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000] Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization. … [L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354]
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawn[A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130] … [L39140] It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 (ACE2) that allows for viral entry into the cell, thereby inhibiting the virus' ability to replicate.
Chikungunya vaccine (live, attenuated)
go.drugbank.com/drugs/DB18701ApprovedInvestigationalIn late 2013, the first cases were identified in the Caribbean, and it has since spread to most of the Americas.[L48786] There are no approved treatments for active chikungunya virus infection. … caused by chikungunya virus.
Lisdexamfetamine
go.drugbank.com/drugs/DB01255ApprovedInvestigational[L48285] Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder [A2230] by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal … [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMefloquine
go.drugbank.com/drugs/DB00358ApprovedIt was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. … The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976.